1. THE BROADEST PORTFOLIO WITH LEADING SCIENCE AND INNOVATION
Galderma has the world’s broadest dermatology portfolio, with clinically proven and synergistic flagship brands. These include Dysport®/Azzalure®, Alluzience® and the first and only ready-to-use liquid neuromodulator created with PEARLTM Technology, which together form the world's second-largest neuromodulator franchise; Restylane®, the original hyaluronic acid filler, backed by 27 years of clinical use and over 65 million treatments worldwide; and Sculptra®, the number-one global biostimulator, in Injectable Aesthetics.
In Dermatological Skincare, the portfolio includes our heritage brand, Cetaphil®, the dermatologist-recommended skincare brand focused on sensitive skin which continuously expands with new product lines and exciting activations; and Alastin®, the premium brand of choice for peri-procedural care and for scientifically-backed restorative daily skincare.
In Therapeutic Dermatology, we are addressing unmet needs in atopic dermatitis and prurigo nodularis, and our ‘pipeline in a product’ biologic, Nemluvio® (nemolizumab), is being investigated for further indications.
To drive long-term sustainable growth, Galderma leverages its leading science and innovation capabilities. We have successfully strengthened our scientific differentiation as well as advanced its pipeline across product categories.
2. GLOBAL SCALE WITH OMNI-CHANNEL EXECUTION EXCELLENCE
With a presence in over 90 countries, Galderma is strategically positioned in attractive and consumer-driven market segments of dermatology, underpinned by high growth and resilient fundamentals. Our global commercial presence has headroom for growth, especially through continued penetration in fast-growing geographies leveraging its synergistic flagship brands.
Galderma’s global reach is deepened and enhanced through omnichannel execution, including a specialized salesforce of over 2,500 employees engaging regularly with healthcare professionals; a network covering over 270,000 retailers, retail stores and pharmacies; and activation through social media engagement with top campaigns reaching more than 450 million impressions.
3. MARKET-LEADING EDUCATION AND SERVICES
Galderma has differentiated value-adding platforms, including market-leading education, scientific engagement and service offerings, which drive penetration and increase loyalty across our portfolio. We continue to lead in education and services, with a strong presence at major events and best-in-class medical aesthetics education and training programs.
With dermatology-focused healthcare professionals at the center of Galderma’s integrated dermatology strategy, we are aiming to train and engage with over 250,000 healthcare professionals by 2030. Our teams are well on track to achieve this target, currently hosting over 10,000 events annually through the Galderma Aesthetics Injector Network (GAIN), a leading provider of medical aesthetics education to practices around the world. We also maintain a solid presence at dermatology congresses globally. Other examples of value-adding offerings include ASPIRE, Galderma’s loyalty program in the U.S. for consumers and healthcare professionals; ASCENT, our education offer for rising practitioners in aesthetics; the Skin Knowledge and Innovation Network (SKIN), which provides healthcare professionals with access to the latest insights, updates and advancements in Therapeutic Dermatology; and the Global Sensitive Skincare Faculty (GSSF), our network of experts supporting research and better care for sensitive skin. In addition to these, we have launched tech-enabled solution such as Cetaphil’s AI Skin Analysis.
